New drug combo targets tough cancers in early trial
NCT ID NCT03065062
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This early-phase study tests a combination of two drugs (palbociclib and gedatolisib) in people with advanced lung, pancreatic, head & neck, or other solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can slow cancer growth. About 75 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.